Acute-phase serum amyloid a in osteoarthritis: regulatory mechanism and proinflammatory properties by DE SENY, Dominique et al.
Acute-Phase Serum Amyloid A in Osteoarthritis:
Regulatory Mechanism and Proinflammatory Properties
Dominique de Seny1*, Gae¨l Cobraiville1, Edith Charlier1, Sophie Neuville1, Nathalie Esser2,
Denis Malaise , Olivier Malaise , Florence Quesada Calvo , Biserka Relic , Michel G. Malaise1 1 1 1 1
1 Laboratory of Rheumatology, GIGA Research, University of Lie`ge, CHU Lie`ge, Liege, Belgium, 2Virology and Immunology Unit, GIGA Research, University of
Abstract
Objective: To determine if serum amyloid A (A-SAA) could be detected in human osteoarthritic (OA) joints and further
clarify if high A-SAA level in joints result from a local production or from a diffusion process from abnormally elevated
plasma concentration. Regulatory mechanism of A-SAA expression and its pro-inflammatory properties were also
investigated.
Methods: A-SAA levels in serum and synovial fluid of OA (n = 29) and rheumatoid arthritis (RA) (n = 27) patients were
measured and compared to matched-healthy volunteers (HV) (n = 35). In vitro cell cultures were performed on primary joint
cells provided from osteoarthritis patients. Regulatory mechanisms were studied using Western-blotting, ELISA and lentiviral
transfections.
Results: A-SAA was statistically increased in OA plasma patients compared to HV. Moreover, A-SAA level in OA plasma and
synovial fluid increased with the Kellgren & Lauwrence grade. For all OA and RA patients, A-SAA plasma level was higher
and highly correlated with its corresponding level in the synovial fluid, therefore supporting that A-SAA was mainly due to
the passive diffusion process from blood into the joint cavity. However, A-SAA expression was also observed in vitro under
corticosteroid treatment and/or under IL-1beta stimuli. A-SAA expression was down-regulated by PPAR-c agonists
(genistein and rosiglitazone) and up-regulated by TGF-b1 through Alk1 (Smad1/5) pathway. RhSAA induced
proinflammatory cytokines (IL-6, IL-8, GRO-a and MCP-1) and metalloproteinases (MMP-1, MMP-3 and MMP-13) expression
in FLS and chondrocytes, which expression was downregulated by TAK242, a specific TLR4 inhibitor.
Conclusion: Systemic or local A-SAA expression inside OA joint cavity may play a key role in inflammatory process seen in
osteoarthritis, which could be counteracted by TLR4 inhibition.
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Introduction
Osteoarthritis (OA) is a degenerative disorder characterized by
a progressive cartilage breakdown, osteophyte formation, sub-
chondral bone thickening and local inflammatory process. It is
now considered as a metabolic disorder since mechanical stress
alone cannot explain the link between obesity and pathology in
non-weight-bearing joints, such as hand OA [1–4].
Recent evidences suggest that chondrocytes can under physi-
ological and pathological conditions synthesize several non-matrix
factors like adipokines that contribute to cartilage degradation
within articular joints [5]. As observed in rheumatoid arthritis
(RA), fibroblast-like synoviocytes (FLS) might play a role in joint
destruction by producing cytokines and metalloproteinases [6].
FLS are also able to secrete adipokines such as leptin [7].
Leptin, adiponectin, resistin and visfatin are the most exten-
sively studied adipokines in OA [5]. However, A-SAA (SAA1 and
SAA2, collectively called A-SAA) has been recently placed on the
front stage of research for its convergence to both inflammation
and metabolic pathways [8,9].
A-SAA is highly produced by the liver after stimulation with
pro-inflammatory cytokines. Its concentration may increase up to
1000-fold during the acute phase of inflammation in regard to
normal condition [10,11]. Besides its influence on lipid metabolism
[12,13], A-SAA is known to participate to immune cells
recruitment at inflammatory sites [14,15] and to induce expression
of pro-inflammatory cytokines [14,16] and matrix metalloprotei-
nases [17]. Across the last decade, several studies attempted to
demonstrate the extra-hepatic production of A-SAA by several
tissues and different cell types of patients with atherosclerosis [18],
Alzheimer disease [19], obesity [9] or RA [20,21]. A-SAA protein
was detected in synovial membrane provided by RA patients as
well as in RA-synoviocytes [20]. A-SAA protein was similarly
detected in the synovial membrane of patients with psoriatic
arthritis, sarcoı¨dosis or other undifferentiated arthritidies [20–22]
PLOS ONE | www.plosone.org 1 June 2013 | Volume 8 | Issue 6 | e66769
    B elgiumLiege,                         
`
`
ege, Belgium. The funders had no role in study
`
`
Liege,                         `
and slightly detected in sections from paraffin-embedded OA
cartilage [23].
A-SAA mRNA was found to be up-regulated by TNF-a, IL-1b
and to a lesser extent by IL-6 in FLS of RA patients [20]. FLS and
chondrocytes capacity of secreting A-SAA at a protein level is
largely unknown. Indeed, data are still inconsistent and even
conflicting in determining if high A-SAA level in joints are due, at
least in part, to a high local production in pathological tissues or if
the A-SAA diffusion into pathological tissues largely depends on its
plasma concentration [14]. Furthermore, molecular and cellular
mechanisms related to A-SAA expression by extra-hepatic cells are
poorly understood. Therefore, to further clarify the role played by
A-SAA as a systemic or local inflammatory marker, A-SAA




Twenty-nine patients with OA and 27 with RA recruited
through community questionnaires, consultations and hospital
outpatient clinics took part in this study. All the patients fulfilled
the established diagnostic criteria for their respective diseases
[24,25]. OA patients were classified according to the Kellgren and
Lawrence grade (K&L) [26]. None of the OA patients were on
intra-articular steroid. Among the 27 RA patients, some of them
received concomitant treatments including methotrexate (MTX)
at a mean dosage of 9.4 mg/week (range 6–15 mg/week) in 11
(40%) of 27 patients and prednisolone at a mean dosage of
8.9 mg/day (range 5–20 mg/day) in 15 (55%) of 27 patients.
Thirty-five healthy volunteers (HV), matched for age [median
(range) yr: 56 (50–64)], gender (56% of female) and BMI [median
(range) Kg/m2: 25 (19–31)] served as the control group. HV were
qualified for entry into the study considering the following
exclusion criteria: any prior history of knee trauma, joint pain,
chronic inflammatory or autoimmune disease, cardiovascular
disease, diabetes, corticosteroid injection or NSAID use. Paired
synovial fluid (SF) and blood samples were simultaneously
collected for each patient.
Ethics Statement
The institutional review boards (Research Ethics Committee) of
the University Hospital, CHU de Lie`ge, Belgium, approved both
the study protocol and the use of verbal informed consent to allow
research procedures on biologic samples or tissues collected in out-
and in-patients during their passage or stay at the CHU de Lie`ge,
as explained in the institutional information booklet written by the
hospital and provided to each patient. Clinicians gave to patients
an oral statement about our research. This statement included
basic elements of our informed consent. Then, clinicians informed
patients about authorizations obtained from the local Research
Ethics Committee to perform studies and showed documents to
those who wanted to read it. Clinicians gave sufficient time to
patients to consider whether or not they wanted to participate in
the research. After allowing the potential subject sufficient time,
clinicians answered to any additional questions patients might
have. Then clinicians obtained patient’s verbal consent to
participate in the research. Strict data management retained
anonymity of participants.
Human primary chondrocytes, FLS and preadipocytes
The cartilage and synovial tissue were obtained from OA
patients during joint replacement. Informed consents were
obtained and experiments approved by the ethics committee of
our academic hospital (CHU, Lie`ge, Belgium). Primary chondro-
cytes and FLS were isolated from human cartilage and synovial
tissue, respectively, as described in [27] [28]. Briefly, primary
chondrocytes (26105 cells/0.5 ml of medium) were seeded in 24-
well plates (BD Biosciences, USA) in triplicate and let to
dedifferentiate or stimulated with indicated reagents at indicated
concentration and defined culture time. FLS (56104 cells/0.5 ml
of medium) were seeded similarly between passages 2–6. After a
defined culture time, cellular supernatants were collected for
ELISA tests and cells were harvested for protein extraction.
Visceral adipose tissue samples were minced and digested with
1.5 mg/ml type I collagenase (Sigma-Aldrich, USA) in PBS for 90
min at 37uC with manually shaking for 5–10 seconds every 15
min. To stop collagenase activity, FBS (10%) was added. After
centrifugation (400 g for 10 min), the floating mature adipocytes
were removed and the stroma vascular fraction (SVF) cell pellet
was resuspended in erythrocyte lysis buffer (155 mmol/l NH4Cl;
5.7 mmol/l K2HPO4; 0.1 mmol/l EDTA; pH 7.3) for 10
minutes. After successive washes and a filtration through a
70 mm nylon cell strainer (BD Biosciences, USA), the SVF cells
were suspended in PBS supplemented with 3% FBS before being
stained for flow cytometry. A part of the SVF cells were stained
with saturing amounts of various fluorochrome-conjugated anti-
bodies such as CD45- phycoerythrin(PE)- cyanin 5 (PC5), CD14-
fluorescein isothiocyanate (FITC), CD3- HorizonTM V500, CD4-
efluor 450, CD8- Perdidin chlorophyll protein (PerCP), CD25-
phycoerythrin (PE), CD127 biotin, streptavidin allophycocyanin
(APC)- efluor 780 (4uC, 20 min, dark). All antibodies were
obtained from Ebioscience, with the exception of CD3-Hor-
izonTM v500, CD8-PercP and CD14-FITC (BD Biosciences,
USA). Flow cytometry was performed on a FACSAria (BD
Biosciences, USA). Data were acquired, analyzed and plotted
using FacsDiva 6.1.2 (BD Biosciences, USA). The subpopulations
of SVF were determined based on sideward scatter, CD45 and
CD14 expression. Preadipocytes were sorted from the
CD45-CD14low stromovascular populations with a purity of .
90% in all samples as described in [29]. Cells (56104 cells/0.5 ml
of medium) were seeded in 24-well plates as described for FLS.
Culture reagents
Culture reagents were purchased as follows: recombinant
human SAA (rhSAA, #300-13, Peprotech, USA), TNF-a
(Biosource, Belgium), IL-1b, IL-6 (R&D systems, USA), rosiglita-
zone, genistein (Alexis Corp., USA), leptin, dexamethasone,
prednisolone, mifepristone, eplerenone, spironolactone, aldoste-
rone, SB431542, lipopolysaccharides (LPS), phenylmethanesulfo-
nyl fluoride (PMSF) (Sigma-Aldrich, USA), insulin (Humulin,
Lilly, France), transforming growth factor b1 (TGF-b1) (GIBCO-
BRL, USA), compound A (CpdA), IgG rabbit polyclonal control,
IgG1 mouse monoclonal (Santa Cruz Biotechnology, USA), anti-
RAGE IgG rabbit polyclonal (Abcam, UK, #ab37647), anti-
CLA1/SR-B1 (BD Biosciences, USA, #610883), lipoxin A4
(Cayman Chemical, Bioconnect, NL), TAK242 (CLI-095, Invivo-
Gen, USA), sulfo-N-succinimidyl oleate (SSO, Santa Cruz
Biotechnology USA) and polymyxin B (Calbiochem Novabio-
chem, USA).
ELISA
A commercially available sandwich enzyme-linked immunosor-
bent assay was used for IL-6, IL-8, GRO-a, MCP-1, MMP-1,
MMP-3 and MMP-13 (R&D Systems, USA) and A-SAA
(Invitrogen, USA) quantification in serum/plasma, synovial fluid
and in cell supernatants according to manufacturer’s instructions.
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RayBio Human cytokines/MMP antibody arrays were performed
according to manufacturer’s instructions (RayBiotech, USA).
Western Blot
Cells were collected, lysed with RIPA buffer (150 mM NaCl,
1% NP40, 0.5% deoxycholate, complete, 0.1% SDS and 50 mM
Hepes pH 7.5) and total proteins separated by SDS-PAGE as
explained earlier in [28]. Membranes were incubated with A-SAA
(Abcam, UK), p-Smad2 (S465/467), Smad2 (L16D3), p-Smad1/5
(S463/465), Smad1 (Cell Signaling Technology, USA) or GAPDH
(Sigma-aldrich, USA) antibodies overnight. Western blots were
visualized with 1:2000 diluted anti-mouse or anti-rabbit (DAKO
A/S, Denmark) antibodies and ECL chemiluminescent reagents
(GE Healthcare, UK).
Endotoxin contamination
Endotoxin level in rhSAA was indicated as below 0.1 ng/mg
according to manufacturer’s instructions. 0.1 ng/mg endotoxin
level is equivalent to 0.5 ng/mL (or 5EU/mL) endotoxin level
when 5 mg of rhSAA is supplied to 1 mL of in vitro culture medium.
To further quantify the endotoxin level of our used solution, 10 mg
rhSAA were diluted in 1 mL PBS and sent for analysis to Lonza
Company (Verviers, Belgium). They reported an endotoxin level
below to 5 pg/mL (or 0.05 EU/mL).
Polymyxin (0.2 mg/mL) or proteinase K (10 mg/mL) was first
incubated with rhSAA or LPS during 45min at 37uC. PMSF
(10 mM) was then added to proteinase K/rhSAA solution for next
45min at 37uC for degrading proteinase K enzyme (a cytotoxic
protease) before cell incubation.
Transfection with lentiviruses expressing Smad1 shRNA
Lentiviral vectors were generated by co-transfecting Lenti-X
293T cells (Clonetech, Belgium) with a pSPAX2 plasmid
(Addgene, Plasmid #12260), a VSV-G encoding vector [30] and
a Smad1 shRNA plasmid (#TRCN0000423087 (shRNA1),
#TRCN0000021780 (shRNA2) or #TRCN0000432716
(shRNA3), Sigma-Aldrich, USA) or with a non target sequence
encoding plasmid (Sigma, Belgium, SHC002). Seventy-two hours
post transfection, viral supernatants were collected, filtrated and
100X concentrated by ultracentrifugation. Lentiviral vectors were
then titrated using qPCR Lentivirus Titration(Titer) Kit (ABM,
USA, LV900). Primary human chondrocytes and FLS were plated
at a density of 26105 cells/0.5 mL in DMEM supplemented with
10% FBS in quadruplicate in 24-well plates. After 7 days of
culture, medium was replaced and cells were infected by lentivirus
at MOI 100. After 72h incubation, cells were stimulated with
prednisolone (1 mM) during 48h. Supernatants and cell lysates
were collected for ELISA test (A-SAA) and Western blotting
(Smad1 and GAPDH), respectively.
Statistical analysis
Statistical analysis was performed by GraphPad Prism software.
A-SAA levels in plasma and SF were compared using the
nonparametric Mann-Whitney Test and were expressed as
median and interquartile range. Other graphs represent averages
of triplicates 6 SD from one representative of three independent
experiments. Correlation coefficients were calculated using
Spearman test. p Values ,0.05 were considered statistically
significant.
Results
A-SAA levels in plasma and synovial fluid
Plasma A-SAA (Figure 1A) levels were significantly higher in the
OA than in the HV group and remained lower in the OA than in
the RA group. A-SAA was easily detected in the synovial fluid of
OA patients but levels remained significantly lower compared to
synovial levels of RA patients. For all OA and RA patients, A-SAA
plasma level was higher compared to its corresponding level in the
synovial fluid in a range of 3 to 44 fold. Plasma A-SAA levels were
significantly correlated to their synovial fluid levels in both OA and
RA patients (Figure 1D–E). A-SAA expression level increased in
both plasma (Figure 1B) and synovial fluid (Figure 1C) according
to the severity of OA, which was characterized by Kellgren &
Lauwrence grades [26].
A-SAA secretion by human OA joint cells and
preadipocytes
Chondrocytes and cartilage shavings. Human primary
chondrocytes when cultured during 14 days in monolayer undergo
cell shape changes, shifting from round form to flattened form, a
process known as dedifferentiation [31,32]. Here we observed that
A-SAA secretion by chondrocytes increased with dedifferentiation
progression, and was even markedly enhanced under prednisolone
(Figure 2A). Prednisolone also enhanced A-SAA secretion by
cartilage shavings (Figure 2E) and primary chondrocytes (still
round shaped, only cultured 48h), an effect reinforced by insuline
(Figure 2B).
Fibroblast-like synoviocytes. FLS were cultured during
48h, 72h and 1 week. However, prednisolone-induced A-SAA
expression was only detected after one week of treatment (Figure
2C). A-SAA expression was also slightly observed in the presence
of IL-1b treatment (Figure 2C).
Visceral preadipocytes and adipose synovium. Visceral
preadipocytes were used as extra-articular cells known as good
responders to inflammatory stimuli for inducing A-SAA expres-
sion. Indeed, we observed that A-SAA protein was slightly
detected under TNF-a or LPS but further enhanced under IL-
1b or prednisolone. Cells remained insensitive to rosiglitazone,
leptin or insulin (Figure 2D). Spontaneous secretion of A-SAA was
observed with adipose synovium explants (Figure 2F).
Glucocorticoid-induced A-SAA expression is GR-
dependent and downregulated in the presence of PPAR-
c agonists
To know the involvement of both glucocorticoid- (GR) and
mineralocorticoid- (MR) receptors in glucocorticoid-induced A-
SAA expression, FLS were stimulated with prednisolone (GR-
dependent glucocorticoid), aldosterone (MR-dependent glucocor-
ticoid) and GR inhibitor (mifepristone) or MR inhibitors
(eplerenone and spironolactone). A-SAA expression level was
increased under prednisolone but not using the MR-dependent
aldosterone (Figure 3A). Furthermore, prednisolone-induced A-
SAA expression was inhibited by the GR inhibitor mifepristone
but not by MR inhibitors (eplerenone and spironoloactone) (Figure
3A). These results suggested that glucocorticoid-induced A-SAA
expression is GR- but not MR-dependent. Similar results were
observed with chondrocytes (data not shown).
FLS and primary human chondrocytes were then treated with
peroxisome proliferators-activated receptor gamma PPAR-c
agonists (genistein and rosiglitazone) with or without prednisolone
and/or insuline. A-SAA expression was induced in both cell types
under prednisolone treatment. Both genistein and rosiglitazone
Acute-Phase Serum Amyloid A in Osteoarthritis
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downregulated A-SAA production level when both cell types were
stimulated with prednisolone alone or combined with insulin
(Figure 3B and 3C). These results showed that A-SAA expression
could be downregulated via the PPAR-c pathway.
Inhibition of A-SAA expression by TGF-b1 in human
primary chondrocytes and FLS
We have demonstrated that glucocorticoids (prednisolone and
dexamethasone) but not compound A (CpdA; a non-steroidal GR
modulator) significantly increased A-SAA production level in
human dedifferentiated chondrocytes (Figure 4A) and in FLS (data
not shown).
Figure 1. A-SAA levels in plasma and synovial fluid – A-SAA according to K&L grades in OA. (A) A-SAA profiles in blood and synovial fluid
(SF) of OA and RA patients compared to those of matched healthy volunteers (HV). The boxes illustrate the 25th-75th percentiles, the horizontal lines
the medians and the vertical lines the minimum and the maximum values. *p,0.05, **p,0.01 and ***p,0.001; non parametrical Mann-Whitney test.
A-SAA expression level in (B) plasma and in (C) synovial fluid (SF) of OA patients classified according to their Kellgren and Lauwrence (K&L) grades.
Correlation of A-SAA levels in plasma vs. A-SAA levels in SF for OA (D) and RA (E) patients.
doi:10.1371/journal.pone.0066769.g001
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Figure 2. A-SAA secretion by several cell types and tissues originated from OA patients. Detection of A-SAA secreted by (A) chondrocytes
along dedifferentiation process, (B) primary human chondrocytes after 48h of treatment, (C) fibroblast-like synoviocytes after 1 week of treatment, (D)
preadipocytes after 1 week of treatment with TNF-a (10 ng/mL), IL-1b (10 ng/mL), IL-6 (10 ng/mL), LPS (10 ng/mL), rosiglitazone (10 mM), leptin
(100 nM), insulin (100 nM) and prednisolone (1 mM), (E) Secretion of A-SAA by cartilage shavings (0.2 g) after 1 week of treatment with prednisolone
(1 mM). (F) Spontaneous secretion of A-SAA by fat synovial membrane after 48h in culture cell medium. A-SAA was determined in the culture
supernatants (ELISA) and in cell extracts (Western blotting).
doi:10.1371/journal.pone.0066769.g002
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We next investigated the role of TGF-b1 in A-SAA expression.
Endogenous- and glucocorticoid-induced A-SAA expressions in
chondrocytes were significantly decreased when cells were
stimulated at day 7 during 48h with TGF-b1 (Figure 4A).
Prednisolone-induced A-SAA expression was even completely
abolished by TGF-b1 when primary chondrocytes were stimulated
earlier at day 1 (Figure 4B).
As TGF-b1 is known to signal via Alk1 (Smad1/5 pathway)
and/or Alk5 (Smad2/3 pathways) [33,34], both pathways were
investigated by three different approaches. First, semi-quantitative
level of p-Smad2, Smad2, p-Smad1/5 and Smad1 were obtained
by Western blotting. Accordingly, it was observed that glucocor-
ticoids increased Smad1/5 phosphorylation [p-Smad1/5] and had
slight effect on Smad2, thereby favouring Alk1-Smad1/5 pathway
as indicated with the positive quantitative [p-Smad 1/5]/p-Smad2
ratio of 1.2 (Figure 4A). On the other hand, TGF-b1 also induced
Smad1/5 phosphorylation but favoured Alk5-Smad2 pathway by
increasing Smad2 phosphorylation ([p-Smad 1/5]/p-Smad2 ratio
of 0.7), counteracting by the way Alk1-Smad1/5 pathway.
Secondly, SB431542, an Alk5-Smad2 inhibitor, partially restored
TGF-b1 inhibition of a previous prednisolone-induced A-SAA
expression (Figure 4B). Finally, lentiviral particles expressing three
different Smad1 shRNA were used to infect dedifferentiated
chondrocytes and FLS. Western blot analysis demonstrated a
Figure 3. Glucocorticoid-induced A-SAA expression is GR-dependent and downregulated in the presence of PPAR-c agonists. (A)
OA-fibroblast-like synoviocytes (FLS) were stimulated during 1 week with prednisolone (1 mM), mifepristone (5 mM), eplerenone (5 mM),
spironolactone (5 mM) and aldosterone (1 mM). Prednisolone-induced A-SAA expression was inhibited by the GR inhibitor mifepristone but not by
MR inhibitors (eplerenone and spironolactone). A-SAA expression was barely detectable under aldosterone treatment, a MR-dependent
glucocorticoid. *a, statistically different from control. *b, statistically different from prednisolone-treated cells. A-SAA expression level by (B) FLS after
1 week and (C) primary human chondrocytes after 72h (A) of treatment with prednisolone (1 mM), genistein (50 mM), rosiglitazone (10 mM) and/or
insulin (100 nM). *a, statistically different from prednisolone-treated cells; *b statistically different from prednisolone- and insulin-treated cells.
doi:10.1371/journal.pone.0066769.g003
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significant decrease of Smad1 expression in infected chondrocytes
(Figure 4C) and FLS (Figure 4D). ELISA analysis showed that
Smad1 silencing resulted in a significant decrease in A-SAA
expression (Figure 4C et 4D). These results suggest that Smad1 is
positively involved in A-SAA expression level in both cell types.
rhSAA-inducing cytokines and MMPs/TIMPs expression
by human chondrocytes and FLS
Raybio human cytokine/MMP/TIMP protein arrays were used
to screen cytokines or MMPs/TIMPs released in the medium by
chondrocytes or FLS in the presence or absence of rhSAA (Figure
S1). Of the 23 cytokines pairs on the array, cytokines up-expressed
by chondrocytes and FLS in the presence of A-SAA were GRO,
IL-8, IL-6 and MCP-1. Of the 10 MMPs/TIMPs pairs on the
array, MMPs secreted by chondrocytes in the presence of A-SAA
were MMP-1, MMP-3 and MMP-13. RhSAA-induced cytokines
and MMPs identified by protein arrays were further validated by
ELISA assays (Figure S2). Increasing concentrations of rhSAA
were tested in the range of 0.5 mg/mL to 5 mg/mL. The effect of
rhSAA on targeted cytokines/MMPs expression in chondrocytes
and FLS was clearly dose dependent (Figure S2).
TLR4 mediates A-SAA-induced cytokines and MMPs
expression
A-SAA is known for interacting with several receptors including
formyl peptide receptor like-1 (FPRL1) [21,35], scavenger
receptor class B member I (SR-B1/CLA1) [36], CD36 [37], toll-
like receptors (TLR2 and TLR4) [38,39] and receptor for
advanced glycation end-products (RAGE) [40,41]. Several inhib-
itors were used to investigate which receptor was involved in A-
SAA-induced cytokines/MMPs secretion by chondrocytes (Figure
5A) and FLS (Figure 5B). We used LX4 known to compete with A-
SAA for FPRL1 binding [14,42], anti-RAGE or anti-SRB1
antibodies to block respective receptors, as well as SSO, which
Figure 4. Balance through either p-Smad2 or p-Smad1/5 signalling. (A) Human chondrocytes were stimulated at day 7 for 48h in the
presence or absence of prednisolone (1 mM), dexamethasone (1 mM), compound A (CpdA) (1 mM) and/or TGF-b (10 ng/mL). A-SAA was determined
by ELISA in the culture supernatants. p-Smad2, Smad2, p-Smad1/5 and Smad1 expression were detected by western blotting in cell extracts.
Quantification was performed using ImageQuant LAS 4000 software. Ratio [p-Smad1/5]/[p-Smad2] is also indicated. (B) Primary human chondrocytes
were stimulated at day 1 during 72h in the presence or absence of prednisolone (1 mM), TGF-b (10 ng/mL) and SB431542 (1.5 mM). A-SAA (ELISA) and
Smad1 expression (Western blotting) in dedifferentiated chondrocytes (C) and FLS (D) transduced with lentiviral particles for shRNA control or three
different shRNA of Smad1. *a, statistically different from control. *b, statistically different from prednisolone-treated cells. *c, statistically different from
prednisolone and TGF-b treated cells.
doi:10.1371/journal.pone.0066769.g004
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irreversibly inhibit CD36. None of these molecules were able to
significantly diminished proinflammatory cytokines secretion
(Figure 5A and B). However, using TAK242, SAA-induced
cytokines and MMPs were significantly decreased in chondrocytes
and FLS (Figure 5A and 5B). TAK242 (resatorvid) is a small
molecule known for binding selectively the intracellular domain of
TLR4 among 10 different human TLRs [43]. All together, these
results showed that TLR4 could mediate SAA-induced cytokines
and MMP, in both chondrocytes and FLS (Figure 5A and B). We
further assessed the specificity of our results by demonstrating that
rhSAA-induced IL-6 expression levels in chondrocytes and FLS
were not due to endotoxin contamination.
Specificity of the results obtained with rhSAA
To rule out the possible LPS effect, we compared IL-6
production induced by rhSAA (5 mg/mL) with those obtained
with LPS 2 ng/mL (20 EU/mL), last concentration being largely
superior to the one detected in our in vitro experiments
(,0.05 EU/mL according to Lonza – 5 EU/mL according to
the supplier). PolymyxinB is a cationic cyclic lipopeptide that binds
stoechiometrically to the lipid A moiety of LPS and blocks its
biological effects, whereas proteinase K is a serine protease that
cleaves peptide bonds at the carboxylic sides of amino acids
degrading A-SAA protein. When rhSAA and LPS were both
combined with polymyxinB, IL-6 induction was drastically
decreased for PolymB/LPS but not for PolymB/rhSAA (Figure
6A–B). Conversely, proteinase K treatment inhibited IL-6
production by rhSAA but not by LPS (Figure 6C–D). These
results suggest that rhSAA, but not LPS, was responsible to pro-
inflammatory effects observed previously.
Discussion
A-SAA level was statistically increased in OA plasma patients
compared to HV. Moreover, A-SAA level in OA plasma and
synovial fluid increased with the Kellgren & Lauwrence grade, a
radiological score used to evaluate the severity of OA [26]. A-SAA
level was statistically increased in RA plasma compared to those in
HV and OA plasma as already described [44,45]. For all OA and
RA patients, A-SAA plasma level was higher compared to its
corresponding level in the synovial fluid in a range of 3 to 44 fold.
Furthermore, A-SAA plasma was highly correlated with its
corresponding A-SAA-synovial fluid level for both OA and RA
pathologies. These two observations were therefore in favour of a
passive diffusion of A-SAA from circulating fluid to the synovial
joint rather than the opposite. Nevertheless, endogenous A-SAA
secretion was also investigated using in vitro studies on primary cells
isolated from OA joints after surgical replacement.
Among cells tested, dedifferentiated chondrocytes and adipose
synovial explants were the only ones able to spontaneously secrete
A-SAA. Primary chondrocytes, when liberated from their extra-
cellular matrix and cultured in a monolayer, shift from their
typical spherical shape to polygonal flattened fibroblast-like shape,
a process termed dedifferentiation [31,32]. This morphological
change is accompanied by changes in gene expression profile,
from cartilage- specific genes (e.g. type –II, -IX, -XI collagen,
aggrecan…) to genes that are rather expressed by fibroblasts (e.g.
type –I, -III, -V collagen, versican…) [46]. Dedifferentiation
constitutes a real problem in the field of articular cartilage repair
as it avoids primary chondrocytes expansion ex vivo and subsequent
re-implantation strategy, also termed autologous chondrocytes
transplantation (ACT) [47]. However, the molecular mechanisms
of signal transduction involved in this process remain poorly
understood [31,32,48,49]. As a consequence, it is of high interest
to better characterize primary chondrocytes vs dedifferentiated
chondrocytes at the molecular level.
Unexpectedly, we have observed that glucocorticoids but no
other investigated mediators were able to induce A-SAA protein
secretion by human primary cells from OA joints origin. Two
prestigious publications have already described the following
paradox of an anti-inflammatory drug (glucocorticoids) inducing
the pro-inflammatory mediator (A-SAA). Bozinovski et al. [42]
have described that glucocorticoids markedly increased SAA in
human macrophages THP-1 cell line in chronic obstructive
pulmonary disease models. Yang RZ et al. [9] have demonstrated
that A-SAA expression was induced by human adipose tissue
explants under dexamethasone stimulation. Of interest our data
have shown a common stimulatory response to corticosteroid for
all cell types but a restricted stimulatory response to cytokines
indicating that A-SAA mechanisms of expression are cell-
dependent: chondrocytes being unresponsive to pro-inflammatory
cytokines, OA fibroblast-like synoviocytes poorly sensitive, and
preadipocytes obtained from visceral tissue fully sensitive. A-SAA
secretion from adipose synovium could therefore arise from
preadipocytes under IL-1b-autocrine or -paracrine secretion by
macrophages, adipocytes or FLS themselves.
Limited number of human cell types including KB oral
epithelial cells [50,51], aortic smooth muscle cells [52] and
adipose tissue explants (35), have demonstrated their capacity of
producing A-SAA under glucocorticoid alone, whereas hepatic cell
such as Hep-3B [53] or HepG2 [50,51] need a preliminary
cytokine-driven induction of A-SAA before corticosteroid en-
hancement [50–52].
Obviously, these publications strengthened the urgent need to
clarify glucocorticoid impact on protein expression level and their
related physiological consequence, mainly in the rheumatology
field where glucocorticoids are abundantly used as therapeutic
treatment.
Thorn et al. had previously detected a putative glucocorticoid
response element (GRE) functionally active in the SAA1 gene
whereas it was disrupted in the SAA2 gene [51]. They had also
described that GR was a required component in mediating the
dexamethasone enhancement of cytokine driven SAA1 transcrip-
tional activity [51] using HepG2 cells. Conde et al. also observed
that dexamethasone was able to increase SAA3 mRNA expression
in murine chondrogenic cell line ATDC-5 [54]. In our cells that
spontaneously respond to corticosteroid exposure, we have shown
that A-SAA secretion was strictly GR dependent as totally
abrogated in the presence of mifepristone, whereas aldosterone
antagonists (eplerenone and sprironolactone) had no effect on A-
SAA production, excluding MR involvement.
Considering our previous work on FLS adipogenesis [7], cells
were cultured in the presence of PPAR-c agonists: genistein and
rosiglitazone. Accordingly, we have observed that PPAR-c
agonists induced a significant inhibition of glucocorticoid-induced
A-SAA production. Yang et al. had already described similar
results on human adipose tissue [9]. They had observed that A-
SAA expression increased in the presence of dexamethasone and/
or insuline and was down-regulated with rosiglitazone. In our
study, increased expression of glucocorticoid-induced A-SAA was
observed in the presence of insulin but for chondrocytes cells only.
Recent studies performed in our laboratory have demonstrated
the inhibitory effects of TGFb1 on leptin expression in FLS and
BM-MSC [55]. ALK1/ALK5 was proposed as a regulatory
balance for leptin expression as already described for MMP13
[33]. In the present work, similar TGFb1 inhibitory effects were
observed for A-SAA protein expression on chondrocytes and FLS.
ALK1/ALK5 was also proposed as a regulatory balance for A-
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Figure 5. TLR4 mediates A-SAA-induced cytokines and MMPs. Blockade of rhSAA (2.5 mg/mL)-induced cytokines and MMPs by specific
inhibitors: lipoxin A4 (LX4; 1 mM), anti-SR-B1 antibody (5 mg/mL) and its isotype IgG1 control antibody (5 mg/mL), anti-RAGE (10 mg/mL) and its
isotype IgG control antibody (10 mg/mL) and TAK242 (1 mM) for FPRL1, SR-B1, RAGE and TLR4 recepetors, respectively, on A) OA primary
chondrocytes and B) OA FLS after 24h of stimulation. Cytokines and MMPs levels were quantified by ELISA in the culture supernatants. *a, statistically
different from control. *b, statistically different from rhSAA-treated cells.
doi:10.1371/journal.pone.0066769.g005
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SAA expression. The protective role of TGFb1 would run through
the ALK5 (Smad2/3) pathway whereas ALK1 (Smad1/5)
pathway would further be considered as pro-inflammatory
enhancing A-SAA expression. Our results strengthened the
hypothesis developed by Blaney et al. for which a shift in balance
toward ALK1 is observed contributing to age-related cartilage
destruction and OA [33]. We support the concept that ALK1
rather than TGFb1 could be a promising therapeutic target.
Besides A-SAA regulatory mechanisms, downstream effects of
A-SAA on cytokines/MMPs expression by chondrocytes and FLS
were assessed using rhSAA protein. Increased expression levels of
IL-6, IL-8, GRO-a, MCP-1, MMP-1, MMP-3, and MMP13 were
observed in a rhSAA-dose dependent manner. It is noteworthy to
Figure 6. Endotoxin contamination - Polymyxin B and Proteinase K digestion treatment. OA fibroblast-like synoviocytes (A–C) and human
primary chondrocytes at day 1 (B–D) were stimulated during 24h with rhSAA (5 mg/mL) and LPS (2 ng/mL) in the presence or not of A–B) polymyxin B
(0.2 mg/mL) or C–D) Proteinase K (10 mg/mL) and PMSF (10 mM). IL-6 level was quantified by ELISA in the culture supernatants. *a, statistically different
from control. *b, statistically different from LPS-induced cells. c*, statistically different from SAA-induced cells.
doi:10.1371/journal.pone.0066769.g006
Acute-Phase Serum Amyloid A in Osteoarthritis
PLOS ONE | www.plosone.org 10 June 2013 | Volume 8 | Issue 6 | e66769
mention that rhSAA concentration used for our in vitro studies was
similar to the one detected in the synovial fluid of our OA cohort.
SAA-induced cytokines [IL-6 [16,41], IL-8 [14] and MCP-1 [14]]
or MMPs [MMP-1, MMP-3 [21] and MMP-13 [17]] or cell
adhesion factors [ICAM/VCAM [15]] were already described in
previous studies but performed on RA- but not OA-synoviocytes.
It was also recently published that A-SAA increased MMP-1,
MMP-3 and MMP-13 mRNA and protein expression levels on
human chondrosarcoma cells SW1353 and human primary
chondrocytes provided from normal articular cartilage [17].
However, we have clearly demonstrated that TAK242 was the
only inhibitor able to block significantly A-SAA-inducing cytokines
and MMPs expression in chondrocytes and FLS. It strongly
suggests that A-SAA is an endogenous TLR4 agonist in OA as
already observed by Sandri et al. in mouse macrophages [39].
Furthermore, it was recently published that sCD14 in synovial
fluid of early OA patients increased IL-8 and IL-6 expression by
FLS in response to both TLR2 and TLR4 ligands [56], therefore
supporting the role of innate immunity in low-grade inflammation
observed within the synovial membrane of OA joints. We further
assessed the specificity of our results by demonstrating that rhSAA-
induced IL-6 expression levels in chondrocytes and FLS was not
due to endotoxin contamination.
Conclusion
We can summarize the data obtained as follows (Figure 7):
Several evidences strongly suggest that A-SAA in the synovial
fluid of OA and RA patients could be mainly due to an increased
level of A-SAA in blood and therefore due to the diffusion process
into the joint cavity. Correlation between the Kellgren &
Lauwrence grades and the synovial fluid (or plasma) levels of A-
SAA support a role in the pathophysiological process of OA.
We have also demonstrated that A-SAA could be secreted by
chondrocytes and FLS but mostly under glucocorticoids treat-
ment. Cytokines (TNF-a, IL-1b and IL-6) or other mediators
(LPS, leptin, insulin) did not induce any detectable A-SAA protein
expression using both cell types. Spontaneous secretion was only
observed using dedifferentiated chondrocytes and adipose synovi-
um. Visceral preadipocytes produced A-SAA under glucocorticoid
stimulation but also responded to cytokine stimuli.
A-SAA expression under glucocorticoid treatment involved GR
but not MR receptor and was down-regulated by two PPAR-c
agonists (genistein and rosiglitazone). A-SAA production could be
under the control of TGF-b, with ALK1 as a stimulatory pathway
and ALK5 as an inhibitory pathway. Finally, rhSAA capacity of
inducing cytokines and MMPs secretion by chondrocytes and FLS
was restricted to TLR4 receptor.
Supporting Information
Figure S1 Human cytokines/MMP/TIMP antibody ar-
rays. Human primary chondrocytes and fibroblast-like synovio-
cytes (FLS) obtained from OA patients were cultured during
24 hours in the presence or absence of recombinant human A-
SAA (5 mg/mL). Human cytokines/MMP/TIMP were detected in
culture supernatants using antibody arrays.
(TIF)
Figure S2 rhA-SAA inducing cytokines/MMPs/TIMPs
expression. A) OA primary chondrocytes and B) OA fibroblast-
like synoviocytes after 24 hours of stimulation.
(TIF)
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